Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Korczynski Sherry reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics reported that Chief Commercial Officer Sherry Korczynski received a grant of 67,500 Performance Stock Units (PSUs). Each PSU represents a contingent right to receive one share of common stock, with no cash paid by the executive at grant.
The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, will vest 100% on March 7, 2028. Performance is tied to a defined “Performance Price,” based on 30‑day average Nasdaq closing prices over two measurement periods, aligning the award’s value with the company’s share performance.
BRAENDER LORI J reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics, Inc. Corporate Secretary Lori J. Braender received a grant of 82,500 Performance Stock Units on March 7, 2025. Each unit represents a contingent right to one share of common stock and measures performance from March 7, 2025 through March 7, 2028.
If earned under the performance formula, the units vest 100% on March 7, 2028, with the award expiring on that date. The filing notes it was submitted late due to an inadvertent administrative oversight.
Aquestive Therapeutics, Inc. filed a Form 3 for Chief Legal Officer Thomas A. Zalewski. The filing lists a holding entry in common stock, with total common shares beneficially owned directly reported as 0 following the reported entry.
Aquestive Therapeutics filed an 8-K after completing an in-person FDA Type A meeting on its Anaphylm™ (dibutepinephrine) sublingual film program for treating Type 1 allergic reactions, including anaphylaxis. The meeting provided preliminary FDA feedback on pharmacokinetic and human factors study designs and on revised packaging.
The company says it is incorporating the FDA’s comments into upcoming studies and plans to submit the human factors protocol for FDA review. Based on this interaction, Aquestive reaffirmed its plan to resubmit the Anaphylm New Drug Application in the third quarter of 2026 and is also advancing regulatory submissions in Canada and the European Union.
Aquestive Therapeutics is reshaping its legal leadership, appointing Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026, while Lori J. Braender steps down from those executive roles and continues as Corporate Secretary.
Braender will provide transition services and receive her current base salary through May 7, 2026, plus a pro rata 2026 bonus, 12 months of severance-style monthly payments equal to 1/12 of her prior base salary and target bonus, and 12 months of continued health and life insurance coverage. All of her unvested equity awards will fully vest on May 7, 2026, and options and similar awards will remain exercisable for at least five years or until their scheduled expirations.
For her ongoing non-executive role, Braender will earn a base salary of $15,000 per month and remain eligible for senior executive benefit plans. To induce Zalewski to join, the company will grant 100,000 Restricted Stock Units and 75,000 stock options under its 2022 Equity Inducement Plan, vesting over three years, with the options carrying a ten-year term and an exercise price set at the closing price on May 8, 2026.
Aquestive Therapeutics Chief People Officer Peter E. Boyd reported equity awards and a mandated tax-related share sale. On March 9, he received 80,000 shares of restricted Common Stock that vest over three annual installments (25%, 25%, 50%), and a non-qualified stock option for 42,500 shares of Common Stock at $4.29 per share, expiring on March 9, 2036, with the same vesting pattern.
On March 10, 29,814 shares of Common Stock were sold at a weighted average price of $4.173 per share solely to cover tax withholding obligations tied to restricted stock unit vesting, as required by the company’s equity plans and not as discretionary trading. After these transactions, Boyd directly holds 338,509 shares of Common Stock plus the newly granted option for 42,500 shares.
Aquestive Therapeutics President and CEO Daniel Barber reported compensation-related equity activity and a mandated tax sale. On March 9, 2026, he received 262,000 shares of restricted Common Stock at no cost and 523,000 non-qualified stock options with a $4.29 exercise price, each vesting 25%, 25%, then 50% over three annual installments. On March 10, 2026, he sold 180,677 Common shares at a weighted average price of $4.173 in trades between $4.17 and $4.33 to cover tax withholding obligations from restricted stock unit vesting, as required by the company’s equity plan, rather than as discretionary trading. After the sale, he directly owned 1,004,753 Common shares and held the newly granted options for 523,000 underlying shares.
Aquestive Therapeutics Chief Legal Officer Lori J. Braender received new equity awards and executed a tax-related share sale. She was granted 80,000 shares of restricted stock, which will vest in three annual installments of 25%, 25%, and 50%. She also received 50,000 non-qualified stock options to buy common stock at $4.29 per share, vesting on the same 25%/25%/50% schedule and expiring in 2036. On March 10, 2026, she sold 40,102 shares of common stock at a weighted average price of $4.173 per share to cover tax withholding obligations from restricted stock unit vesting, a mandated “sell to cover” transaction rather than a discretionary trade. After these transactions, she directly holds 442,879 shares of common stock.
Aquestive Therapeutics SVP Melina Cioffi reported a mix of stock grants and tax-related sales. She received 100,000 shares of restricted common stock at no cost and a grant of options for 75,000 shares at a $4.29 exercise price, both vesting over three annual installments of 25%, 25%, and 50%.
On a separate date, she sold 25,311 common shares at a weighted average price of $4.173 per share to cover tax withholding tied to restricted stock unit vesting, a transaction mandated by the company’s equity plans rather than a discretionary trade. After these transactions, she directly holds 274,867 common shares.
Aquestive Therapeutics Chief Financial Officer Ernest A. Toth Jr. reported a mix of equity compensation awards and a related share sale. He received 95,000 shares of common stock as a grant and a non-qualified stock option for 70,000 shares of common stock with a $4.29 exercise price, expiring on March 9, 2036. Both the restricted stock and options vest over three annual installments of 25%, 25%, and 50%. On March 10, 2026, he sold 58,254 shares of common stock at a weighted average price of $4.173 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations from the vesting of restricted stock units and were mandated under the company’s equity incentive plan, rather than being discretionary trades. After the sale, he directly held 376,112 shares of common stock and the newly granted option for 70,000 shares.